73,278 Shares in Psyence Biomedical Ltd. (NASDAQ:PBM) Purchased by Essential Planning LLC.

Essential Planning LLC. bought a new stake in shares of Psyence Biomedical Ltd. (NASDAQ:PBM) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,278 shares of the company’s stock, valued at approximately $163,000. Essential Planning LLC. owned 1.11% of Psyence Biomedical at the end of the most recent reporting period.

Psyence Biomedical Stock Performance

Shares of NASDAQ:PBM opened at $0.76 on Friday. Psyence Biomedical Ltd. has a 1 year low of $0.74 and a 1 year high of $140.25. The business has a 50 day simple moving average of $1.43 and a two-hundred day simple moving average of $5.70.

Psyence Biomedical (NASDAQ:PBM) last announced its earnings results on Thursday, January 23rd. The company reported $0.51 earnings per share (EPS) for the quarter.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.